Loading...
•
Aug 31, 2022
Nurix Q3 2022 Earnings Report
Nurix reported third quarter fiscal year 2022 financial results
Key Takeaways
Nurix Therapeutics reported a net loss of $45.7 million for the third quarter ended August 31, 2022. The company's cash, cash equivalents, and marketable securities totaled $413.6 million as of August 31, 2022. They also completed two registered direct offerings in July raising gross proceeds of $95 million.
Completed two registered direct offerings in July raising gross proceeds of $95 million
Maintained a strong financial position with $413.6 million in cash and marketable securities as of August 31, 2022
Expanded leadership team and board of directors with experienced industry leaders
Announced multiple presentations at upcoming SITC 2022 annual meeting, including initial PK/PD data for NX-1607 program
Revenue by Segment
Forward Guidance
Nurix anticipates presenting additional clinical results from the Phase 1a portion of the NX-2127 trial and expects to have initial PK/PD data from the Phase 1a portion of the NX-5948 study by the end of 2022. Nurix anticipates providing a clinical update from the run-in portion of the DeTIL-0255 Phase 1 study by the end of 2022.
Positive Outlook
- NX-2127: Anticipates presenting additional clinical results from the Phase 1a portion of the trial by the end of 2022
- NX-5948: Expects to have initial PK/PD data from the Phase 1a portion of the study by the end of 2022
- NX-1607: Expects to present initial PK/PD data from the Phase 1a stage of the study at the SITC 2022 annual meeting
- DeTIL-0255: Anticipates providing a clinical update from the run-in portion of the DeTIL-0255 Phase 1 study by the end of 2022
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...